Key facts
- Myomaker Bio’s last known valuation is $2.4M (Feb 2026).
- It has raised $430K; the latest was Early Stage VC ($430K) in Feb 2026.
- Notable investors include SFC Capital, ICURe, Loughborough University.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Myomaker Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Myomaker Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Myomaker Bio
Developer of human muscle platforms designed for preclinical drug discovery, delivering data that boosts clinical trial success by replicating human muscle. The company's platform monitors muscle biology in health, exercise, disease injury and regeneration and can be applied across a range of preclinical muscle models, the models model muscle morphology and function and have been validated using pharmaceutical agents, enabling researchers to get preclinical muscle biology systems as per their requirement.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2023
- Employees
- 8
- Website
- myomakers.com/
- Ownership
- Privately Held (backing)
Myomaker Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Myomaker Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Myomaker Bio in its N-PORT filings yet. We sweep new filings monthly.